Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miki Ando

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
The Journal of Veterinary Medical Science|December 7, 2025
Anti-tumor effect of a histone deacetylase inhibitor on canine malignant melanomaToshio Li, Hayato Shibahara, Daiki Kato, et al.
Cardio-Oncology (London, England)|July 19, 2025
The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsNaoki Watanabe, Tomoiku Takaku, Noriyoshi Iriyama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 10, 2024
Butyrate, Valerate, and Niacin Ameliorate Anaphylaxis by Suppressing IgE-Dependent Mast Cell Activation: Roles of GPR109A, PGE2, and Epigenetic RegulationKazuki Nagata, Daisuke Ando, Tsubasa Ashikari, et al.
International Journal of Hematology|April 8, 2024
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study GroupNoriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, et al.
Journal of Clinical Medicine|July 13, 2024
A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification"Hideaki Nitta, Haruko Takizawa, Toru Mitsumori, et al.
International Journal of Hematology|May 2, 2023
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effectsMichihide Tokuhira, Yuta Kimura, Takayuki Tabayashi, et al.
International Journal of Hematology|December 13, 2025
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemiaKohjin Suzuki, Tomoiku Takaku, Naoki Watanabe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 10, 2021
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphomaSakiko Harada, Miki Ando, Jun Ando, et al.
Cell Reports. Medicine|December 13, 2023
iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancerYoshiki Furukawa, Midori Ishii, Jun Ando, et al.
Internal Medicine (Tokyo, Japan)|April 2, 2023
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical PracticeShun Tsuchiya, Tomoiku Takaku, Naoki Watanabe, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
The Journal of Veterinary Medical Science|December 7, 2025
Anti-tumor effect of a histone deacetylase inhibitor on canine malignant melanomaToshio Li, Hayato Shibahara, Daiki Kato, et al.
Cardio-Oncology (London, England)|July 19, 2025
The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsNaoki Watanabe, Tomoiku Takaku, Noriyoshi Iriyama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 10, 2024
Butyrate, Valerate, and Niacin Ameliorate Anaphylaxis by Suppressing IgE-Dependent Mast Cell Activation: Roles of GPR109A, PGE2, and Epigenetic RegulationKazuki Nagata, Daisuke Ando, Tsubasa Ashikari, et al.
International Journal of Hematology|April 8, 2024
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study GroupNoriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, et al.
Journal of Clinical Medicine|July 13, 2024
A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification"Hideaki Nitta, Haruko Takizawa, Toru Mitsumori, et al.
International Journal of Hematology|May 2, 2023
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effectsMichihide Tokuhira, Yuta Kimura, Takayuki Tabayashi, et al.
International Journal of Hematology|December 13, 2025
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemiaKohjin Suzuki, Tomoiku Takaku, Naoki Watanabe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 10, 2021
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphomaSakiko Harada, Miki Ando, Jun Ando, et al.
Cell Reports. Medicine|December 13, 2023
iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancerYoshiki Furukawa, Midori Ishii, Jun Ando, et al.
Internal Medicine (Tokyo, Japan)|April 2, 2023
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical PracticeShun Tsuchiya, Tomoiku Takaku, Naoki Watanabe, et al.
Pageof 9